Expert Financial Analysis and Reporting

At the request of some subscribers to my website, I have been asked to take a look at the bull and bear case on Spectrum Pharmaceuticals and try to fairly represent the positives and negatives of each point of view. There is strong bearish sentiment as short interest accounts for 52% of the float. For […]

Investment Opinion I believe that the issuance of a Complete Response Letter to Bristol-Myers Squibb (BMY) and Pfizer (PFE) for the use of Eliquis to prevent stokes caused by atrial fibrillation is a minor setback and believe that the issue can be resolved and the product approved by October at the earliest and April of […]

I have just published a new report and initiated coverage of InSite Vision (INSV, $0.30) with a Buy. The core technology of InSite Vision is its DuraSite drug delivery system that delivers drugs more effectively to the eye. The continual blinking of the eye can quickly wash out topical formulations and in order to retain […]

I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015 price target is $5.00+. The recommendation is keyed to the projected approval of APF530 for the treatment of chemotherapy induced nausea and vomiting in early 2013 and launch in the US in mid-2013. Most newly […]

Key Points Dendreon has made a sweeping change in management by bringing in John Johnson, who was serving as a board member, to be the new President, CEO and Chairman-elect of the Board of Directors. He immediately replaces Mitchell Gold as CEO and Richard Brewer has stepped down as Chairman of the Board. Mr. Gold […]

Conclusions I think that most physicians and investors were aware that the analysis of Dendreon’s (DNDN) Provenge in the Phase III IMPACT Trials understated its effect on survival because of the use of frozen Provenge (Frovenge) in the control group. In a new scientific paper, the authors concluded that after adjusting for this factor, the median […]

Investment Conclusion JNJ has gone through three very difficult years as EPS increased only slightly from $4.63 in 2009 to $5.00 in 2011. The most important challenge faced was the loss of patents on the major drugs, Risperdal, Topamax, Levaquin, Duragesic and Concerta which saw aggregate sales drop from $5.8 billion in 2009 to an […]

Investment View I believe that Transcept’s (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success. I am anticipating that Transcept’s marketing partner Purdue Pharmaceuticals will launch the product in mid-2012. There was a time when new product approvals and launches produced investor exuberance. Now they seem to be met […]

Investment View of the Proposed Acquisition Cubist announced today that it had signed a definitive agreement to acquire Adolor.   Adolor has been one of my four recommendations. My price target was $4.50 in 2013 based on sales and earnings of Entereg alone and before taking into account the potential for ADL5945. Please refer to […]

Investment Opinion Orexigen’s (OREX) anti-obesity drug Contrave has been given new life as the FDA reversed a previous position that would have required a cardiovascular outcomes trial involving 60,000 to 100,000 patients and which might have taken four to six years to complete in order to gain US approval for Contrave. In a press release […]